Published in AIDS Weekly, April 16th, 2007
There is an urgent need for new antiretroviral drugs due to rates of failure in existing combination antiretroviral therapies. Rates of failure after six years are currently 21 per cent for treatment experienced patients and 11 per cent for those new to treatment.
The current study looked at the effectiveness of the new 'protease-inhibitor' darunavir, when used in conjunction with a boosting (low) dose of the existing antiretroviral drug ritonavir.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.